For Q1 FY2026 ended March 31, 2026, Tenax Therapeutics reported no revenue and a net loss of $15.7 million, a 51% increase from the prior year. Operating loss was $16.6 million, up 46% year-over-year. Diluted EPS was -$0.35, a 25% decline. The company held $118.8 million in cash and $114.7 million in equity, with no long-term debt.
•No revenue generated in Q1 FY2026.
•Net loss widened to $15.7 million from $10.4 million in Q1 FY2025.
•Operating loss increased to $16.6 million from $11.3 million.
•Cash and cash equivalents stood at $118.8 million as of March 31, 2026.
Informational summary based on SEC XBRL figures · generated by deepseek-v4-flash. Not investment advice.
Tenax Therapeutics, Inc., a development-stage pharmaceutical company develops novel cardiopulmonary therapies in the United States. It develops TNX-101, TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension in heart failure with preserved ejection fraction and associated pulmonary hypertension TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia. Founded in 1967 and headquartered in Chapel Hill, North Carolina, Tenax Therapeutics was formerly known as Oxygen Biotherapeutics, Inc. before rebranding in September 2014.
Tenax Therapeutics, Inc. is a development-stage pharmaceutical company focused on developing novel cardiopulmonary therapies. Its pipeline includes TNX-101, TNX-102, and TNX-103 (levosimendan), which have completed Phase II clinical trials for treating patients with pulmonary hypertension in heart failure with preserved ejection fraction and associated pulmonary hypertension. Additionally, the company is developing TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia. Tenax Therapeutics is headquartered in Chapel Hill, North Carolina, and was originally founded in 1967. It was formerly known as Oxygen Biotherapeutics, Inc. before rebranding in September 2014.
Where is Tenax Therapeutics listed and in which currency?
Tenax Therapeutics, Inc. is listed on the Nasdaq Capital Market (NasdaqCM) under the ticker symbol TENX. Its securities trade in United States Dollars (USD). The company is based in the United States, and its stock is accessible to investors through major US brokerage platforms.
What sector and industry does Tenax Therapeutics operate in?
Tenax Therapeutics operates in the Healthcare sector, specifically within the Biotechnology industry. As a biotechnology company, it focuses on research and development of pharmaceutical therapies, particularly for cardiopulmonary conditions and chronic myeloid leukemia. The company is in the development stage, meaning its products have not yet received regulatory approval for commercial sale.
Where is Tenax Therapeutics headquartered and what is its history?
Tenax Therapeutics is headquartered in Chapel Hill, North Carolina, United States. The company was founded in 1967 and has undergone a name change: it was formerly known as Oxygen Biotherapeutics, Inc. before rebranding to Tenax Therapeutics in September 2014. The company primarily serves the US market, focusing on developing therapies for unmet medical needs in cardiopulmonary diseases and oncology.
What are the main product candidates of Tenax Therapeutics?
Tenax Therapeutics' main product candidates include TNX-101, TNX-102, and TNX-103, which are formulations of levosimendan. These have completed Phase II clinical trials for the treatment of pulmonary hypertension in heart failure with preserved ejection fraction and associated pulmonary hypertension. Another candidate is TNX-201 (imatinib), a tyrosine kinase inhibitor intended for chronic myeloid leukemia. All candidates are in development, and the company has not yet commercialized any products.